Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin

Journal of Pharmaceutical Sciences

Volumn 93, Issue 9, 2004, Pages 2374-2387

  Kim, Yu C ^a   Kwon, Jong W ^b   Kim, Won G ^b   Lee, Inchul ^c   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c University of Ulsan   (South Korea)

Author keywords

DA 8159; DA 8164; Diabetes mellitus; Pharmacokinetics; Rats; Streptozotocin

Indexed keywords

5 [2 PROPYLOXY 5 (AMINOSULFONYL)PHENYL] 1 METHYL 3 PROPYL 1,6 DIHYDRO 7H PYRAZOLO[4,3 D]PYRIMIDIN 7 ONE; CYTOCHROME P450 3A1; DA 8164; DRUG METABOLITE; SILDENAFIL; STREPTOZOCIN; UDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CLEARANCE; FIRST PASS EFFECT; IN VITRO STUDY; KIDNEY CLEARANCE; LIVER MICROSOME; MALE; MICTURITION; NONHUMAN; PENIS ERECTION; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 4344629549     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20144     Document Type: Article

References (39)

1. Gwilt PR, Nahhas RR, Tracewell WG. 1991. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 20:477-490.
2. Nadai M, Yoshizumi H, Kuzuya T, Hasegawa T, Johno I, Kitazawa S. 1990. Effects of diabetes on disposition and renal handling of cefazolin in rats. J Pharmacol Exp Ther 18:565-570.
3. O'Connor P, Feely J. 1978. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin Pharmacokinet 13:345-364.
4. Watkins JB 3rd, Noda H. 1986. Biliary excretion of organic anion in diabetic rats. J Pharmacol Exp Ther 239:467-473.
5. Pickup JC, Williams G. 1991. Textbook of diabetes, vol. 1. Oxford, UK: Blackwell Scientific Publications, pp 151-155.
6. Watkins JB 3rd, Sanders RA. 1995. Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 47:1-23.
7. Carnovale CE, Marinelli RA, Rodriguez Garay EA. 1986. Bile flow decrease and altered bile composition in streptozotocin-treated rats. Biochem Pharmacol 35:2625-2628.
8. Watkins JB 3rd, Sherman SE. 1992. Long-term diabetes alters the hepatobiliary clearance of acetoaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 260:1337-1343.
9. Park JM, Moon CH, Lee MG. 1996. Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 93:343-352.
10. Price VF, Jollow DJ. 1986. Strain differences in susceptibility of normal and diabetic rats to acetaminophen hepatotoxicity. Biochem Pharmacol 35:687-695.
11. Choi SJ, Ji HY, Lee H-Y, Kim DS, Kim WB, Lee HS. 2002. In vitro metabolism of a novel phosphodiesterase-5 inhibitor DA-8159 in rat liver preparations using liquid chromatography/electrospray mass spectrometry. Biomed Chromatogr 16:395-399.
12. Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB. 2002. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 25:873-878.
13. Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB. 2000. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 23:471-476.
14. Kang MJ, Yoon WH, Kim ON, Lee MG. 1995. Effects of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of furosemide in rats. J Clin Pharm Ther 20:13-21.
15. Ahn BO, Kang KK, Ahn GJ, Kwon JW, Kim WB, Kang KS, Lee YS. 2003. Efficacy of DA-8159, a new PDE 5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury. Int J Impot Res 15:405-411.
16. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. 2000. Factors influencing the protein binding of a new phophodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291.
17. Kim SH, Kim WB, Lee MG. 1999. Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats. Drug Metab Dispos 27:710-716.
18. Litterst CL, Mimnaugh EG, Regan RL, Gram TE. 1975. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 3:259-265.
19. Shim HJ, Lee EJ, Jung YH, Kim SH, Kim SH, You M, Kwon JW, Kim WB, Lee MG. 2002. Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal 30:527-533.
20. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
21. Lineweaver H, Burk D. 1934. The determination of enzyme dissociation constants. J Am Chem Soc 56:658-666.
22. Shim HJ, Kim YC, Park KJ, Kim DS, Kwon JW, Kim WB, Lee MG. 2003. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects. J Pharm Sci 92:2185-2195.
23. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
24. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
25. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
26. Chiou WL. 1979. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 68:1067-1069.
27. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
28. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to rational regimens. J Pharm Sci 69:90-91.
29. Mulay S, Varma DR. 1984. Influence of streptozotocin-diabetes on the pharmacokinetics, placental transfer and tissue localization of dexamethasone in rats. Br J Pharmacol 83:139-144.
30. Lewis DFV. 1996. Substrate specificity and metabolism. In: Cytochromes P450. Structures, function and mechanism. Bristol, PA: Talyor & Francis, p 123.
31. Chiou WL. 1986. A new simple approach to study the effect of changes in urine flow and/or urine pH on renal clearance and its applications. Int J Clin Pharmacol Ther Toxicol 24:519-527.
32. Lee MG, Chiou WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
33. Mehvar R. 1991. Effect of experimental diabetes mellitus on the pharmcokinetics of atenolol enantiomers in rats. J Pharm Sci 80:207-211.
34. Zysset T, Tlach C. 1987. Altered liver function in diabetes: Model experiments with aminopyrine in the rat. J Pharmacol Exp Ther 240:271-276.
35. Nakashima E, Matsushita R, Takeda M, Nakanishi T, Ichimura F. 1992. Comparative pharmacokinetics of cefoperazone and cephradine in untreated streptozotocin diabetic rats. Drug Metab Dispos 20:730-735.
36. Watkins JB 3rd, Dykstra TP. 1987. Alterations in biliary excretory function by streptozotocin-induced diabetes. Drug Metab Dispos 15:177-183.
37. Chung SY, Han KS, Shon SK, Chang MS, Lee MG. 1999. Pharmacokinetics of a new proton-pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with streptozotocin-induced diabetes mellitus. J Pharm Pharmacol 51:929-934.
38. D'Souza MJ, Solomon HM, Fowler LC, Pollock SH. 1988. Pharmacokinetics of cyclosporine in streptozotocin-induced diabetic rats. Drug Metab Dispos 16:778-780.
39. (14) C]diazepam in the streptozotocin-diabetic rat. Xenobiotica 14:751-760.